Respiratory Inhalers Market to Surge Past US$ 44.8 Billion by 2025

Coherent Market Insights

Coherent Market Insights

Coherent Market Insights is a leading market research Publisher which offers report on “Respiratory Inhalers Market to Surge Past US$ 44.8 Billion by 2025”.

SEATTLE, WASHINGTON, UNITED STATES, December 18, 2017 /EINPresswire.com/ — The Global Respiratory Inhalers Market, by Product Type (Dry Powder Inhalers (Single Unit Dose, Multi Dose and Multi Unit Dose), Metered Dose Inhalers and Nebulizers (Compressed, Mesh and Ultrasonic Inhalers), by Application (Asthma, Chronic Obstructive Pulmonary Disease, Pulmonary Arterial Hypertension and Cystic Fibrosis), by Technology (Digital and Manual), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 27,424.4 million in 2016 and is projected to exhibit a CAGR of 5.7% over the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights.

Chronic obstructive pulmonary disease (COPD) is a life-threatening disease affecting the lungs characterized by acute breathlessness. In 2015, it was estimated that around 3 million deaths occurred due to sever Chronic Obstructive Pulmonary Disease (COPD), with 90% fatalities reported in low and middle income countries. The two most common forms of COPD include Chronic Bronchitis and Emphysema. According to American Lung Association (ALA), in 2011, over 24 million people in the U.S. suffered from COPD, including 10 million Chronic Bronchitis and over 4.7 million Emphysema cases. The major reason for chronic obstructive pulmonary disease is exposure to tobacco smoke through active or passive smoking. Most chronic obstructive pulmonary disease cases are preventable by avoiding tobacco smoking. However, countries need to adopt the WHO Framework Convention on Tobacco Control (WHO-FCTC) and follow the MPOWER package of measures so that non-smoking becomes the norm globally.

Request Sample copy of report@ https://www.coherentmarketinsights.com/insight/request-sample/227

Asthma is also one of the prime conditions leading to respiratory, disease which is characterized by recurring attacks of panting and wheezing. The severity and frequency of asthma varies according to individual. According to Center for Disease Control and Prevention (CDC), in 2015, 25 million people (1 in 13) in the U.S. were suffering from asthma. Under 18 age group, 6.2 million people suffered from asthma. Each year asthma accounts for 14.2 million physician office visits, and 1.8 million emergency visits.

Browse 32 Market Data Tables and 25 Figures spread through 195 Pages and in-depth TOC on Respiratory Inhalers Market by Product Type (Dry Powder Inhalers (Single Unit Dose, Multi Dose and Multi Unit Dose), Metered Dose Inhalers and Nebulizers (Compressed, Mesh and Ultrasonic Inhalers), by Application (Asthma, Chronic Obstructive Pulmonary Disease, Pulmonary Arterial Hypertension and Cystic Fibrosis), by Technology (Digital and Manual), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2025

According to Canadian Lung Association (CLA), in 2014, 2.5 million people in Canada suffered from asthma, including 1 million males and 1.4 million females. The number of people having asthma was 0.9 million in Ontario, 0.6 million in Quebec, 0.3 million in British Colombia, and Alberta states of Canada. According to Health and Safety Executive (HSE), an U.K based organization, each year in the U.K 200 to 300 new cases of occupational asthma, 4,000 COPD deaths, 200 to 300 new cases of Pneumoconiosis, and 20-50 new cases of Silicosis were reported. In 2015, it also reported 2,542 mesothelioma and 467 asbestos related deaths.

To know the latest trends and insights prevalent in the Respiratory Inhalers Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/respiratory-inhalers-market-227

Inhalers play a pivotal role in treatment of asthma and chronic obstructive pulmonary disease. The importance of the inhalation is delivery of medicines that directly acts on air passage and lungs. This signifies the higher concentrations of drug at target site, with lower systemic exposure thus also have low adverse effects than the oral or intravenous administration of drug. The drawback of inhalers are that it leads to suboptimal use and low efficacy. The design of inhalers also plays an important role in drug deposition, the characteristics of the inhaled medicine, and on the ability of the patient to use the device.

Key takeaways of the market:

The global respiratory inhalers market is expected to expand at a CAGR of 7% during the forecast period (2017–2025) as there exists a huge unrealized market especially in Asia Pacific, Latin America, Middle East and Africa
Asthma, a therapeutic application segment is expected to dominate the market throughout the forecast period with increasing prevalence of asthma

North America is expected to dominate the market, owing to the increasing usage of smart inhalers during the forecast period
Some of the major players involved in global respiratory inhalers market are AstraZeneca, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc, Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding and Teva Pharmaceutical Industries Ltd.

The key players are focusing on combinational therapies, which will drive the market forward

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Mr. Shah
Coherent Market Insights
+1-206-701-6702
email us here


Source: EIN Presswire

Implantable Drug Delivery Devices Market to Surpass US$ 18.3 Billion Threshold by 2025 Globally

Coherent Market Insights

Coherent Market Insights

Coherent Market Insights is a leading market research Publisher which offers research report on “Implantable Drug Delivery Devices Market”.

SEATTLE, WASHINGTON, UNITED STATES, December 18, 2017 /EINPresswire.com/ — The Global Implantable Drug Delivery Devices Market by Product Type (Drug infusion pumps, Intraocular drug delivery devices, Contraceptive drug delivery devices and Stents (Drug eluting stents and Bio absorbable stents), by Technology (Biodegradable Implants and Non Bio degradable Implants), by Application (Ophthalmology, Cardiovascular, Birth Control/Contraception and Others) and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 9,554.4 million in 2016 and is projected to exhibit a CAGR of 7.6% over the forecast period (2017 – 2025), as highlighted in a new report published by Coherent Market Insights. Factors such as growing aging population and incidence of diseases such as cardiovascular diseases, diabetic retinopathy are the driving factors for the growth of the global implantable drug delivery devices market over the forecast period.

Request Sample copy of report@ https://www.coherentmarketinsights.com/insight/request-sample/1103

Implantable drug delivery devices allow several site specific administration where the drug is needed most for the treatment. Devices allows for sustained release of a therapeutic agent and administer significant lower dose of the drug, which minimize side effects. In 2014, Alimera Sciences, Inc. received U.S. FDA approval for Iluvien for the treatment of diabetic macular edema. Iluvien implant is a tiny cylindrical tube inserted into the back of an eye. It is designed to provide a low daily dose of fluocinolone acetonide, a corticosteroid.

In 2015, the World Health Organization (WHO) estimated that around 17.7 million people died due to cardiovascular disease. Considering the huge patient pool, market players have developed bio absorbable stents. The bio-absorbable stents is expected to show an exponential growth during the forecast period due the fact that this stent is gradually resorb and cleared from the body. Bio absorbable stents overcomes the drawback of metal drug eluting stents. In 2017, Reva Medical Inc., received CE mark approval in Europe for Fantom (sirolimus-eluting bioresorbable coronary scaffold). CE marking is a certification mark that confirms with health, safety, and environmental protection standards for products sold within the European Economic Area (EEA).

Browse 38 Market Data Tables and 28 Figures spread through 144 Pages and in-depth TOC on Implantable Drug Delivery Devices Market by Product Type (Drug infusion pumps, Intraocular drug delivery devices, Contraceptive drug delivery devices and Stents(Drug eluting stents and Bio absorbable stents)), by Technology (Biodegradable Implants and Non Bio degradable Implants), by Application (Ophthalmology, Cardiovascular, Birth control/Contraception and Others) and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) – Global Forecast to 2025

To know the latest trends and insights prevalent in the Implantable Drug Delivery Devices Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/implantable-drug-delivery-devices-market-1103

Diabetic Macular Edema is a growing health problem and the number of cases are increasing due to prevalence of diabetes. According to National Diabetes Statistics, as of 2015 an estimated 30.3 million people of all ages had diabetes in U.S. Hence, manufacturers are actively working on research and development of the implant drug delivery devices field which are biodegradable. In 2014, Allergan received U.S. FDA approval for revised indication for Ozurdex (dexamethasone intravitreal implant) for the treatment of diabetic macular edema. Ozurdex is sustained-release biodegradable steroid implant.

Key Takeaways of the Implantable Drug Delivery Devices Market:

The global implantable drug delivery devices market is expected to exhibit a CAGR of 6% over the forecast period (2017 – 2025), owing to the growth in potential markets, especially in Asia Pacific and Latin America. North America accounted for major market share in 2016

Robust developments in the biodegradable implant products is expected to drive the implantable drug delivery devices market

Cardiovascular application hold the major market share and will show rapid growth due to the introduction of bio-absorbable stents in 2012, which in turn is expected to boost the growth of implantable drug delivery devices market

Some major players operating in the implantable drug delivery devices market are Boston Scientific Corporation, Bayer Healthcare, Medtronic, Allergan plc, Abbott Laboratories, Bausch and Lomb Inc., Elixir Medical Corporation, Riva Medical Inc., Merck & Co., Inc and Alimera Sciences

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Mr. Shah
Coherent Market Insights
+1-206-701-6702
email us here


Source: EIN Presswire

Protein Assays Market to Surge to US$ 3.65 Billion by 2025

Coherent Market Insights

Coherent Market Insights

Coherent Market Insights is a leading market research Publisher which offers research report on “Protein Assays Market to Surge to US$ 3.65 Billion by 2025”.

SEATTLE, WASHINGTON, UNITED STATES, December 18, 2017 /EINPresswire.com/ — The Global Protein Assays Market, by Product Type (Reagents and Kits, Instruments), by Technology Type (Absorbance-based Protein Assays, Colorimetric Protein Assays, Fluorescence-based Protein Assays), by Assay Type (Dye Binding Assays, Copper-Ion based Assays, Test Strip based Assays and Other Protein Assays) and by End User (Pharmaceutical and Biotechnology Companies, Clinical Laboratories, Hospitals and Academic Research Institutes) was valued at US$ 1,384.7 million in 2016 and is projected to exhibit a CAGR of 11.5% over the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights.

Request Sample copy of report@ https://www.coherentmarketinsights.com/insight/request-sample/1087

Protein quantification is a process in protein extraction in biochemistry and molecular biology labs that involves protein extraction, analysis, or labeling. Quantification of protein is required for protein sample and analysis by electrophoresis or chromatography or any other immunochemical techniques. Commonly used protein assays are Bradford, Lowry, BCA, and UV spectroscopic protein assays. In April 2017, Millipore Sigma launched a new Single Molecule Counting Platform, SMCxPROTM, which is based on the principle of immunoassay and it enables precise and sensitive detection over conventional methods. Increasing investments of pharmaceutical companies in protein assays is leading to development of various drugs. Protein assays initiatives have led to new discoveries and development of treatments tailored for specific characteristics such as genetic makeup or genetic profile of an individual tumor that helps to offer relatively better and effective treatment methods. In 2015, According to a publication by Pharmaceuticals Research and Manufacturers of America (PhRMA) — a trade group representing companies in the pharmaceutical industry in the U.S.— the member organizations (pharmaceutical companies) of PhRMA invested around US$ 58.8 billion on R&D, accounting for the largest of all the biopharmaceutical R&D spending in the U.S, in 2015.

Browse 29 Market Data Tables and 33 Figures spread through 180 Pages and in-depth TOC on " Protein Assays Market, by Product Type (Reagents and Kits, Instruments), by Technology Type (Absorbance based Protein Assays, Colorimetric Protein Assays, Fluorescence based Protein Assays), by Assay Type (Dye Binding Assays, Copper-Ion based Assays, Test Strip based Assays and Other Protein Assays), by End User (Pharmaceutical and Biotechnology Companies, Clinical Laboratories, Hospitals and Academic Research Institutes) and by Region – Global Forecast to 2025"

Asia Pacific market is expected to witness highest growth in the global protein assays market over the forecast period, owing to rising application of protein content determination in pharmacy and biotechnology. Increasing private-public partnership for genetic analysis has aided in the market growth. Rising biotechnology and life sciences sector in this region as well as increasing focus on research and development by the top market players is another factor for growth of the market. For instance, in January, 2016, Thermo Fisher Scientific Inc. acquired Affymetrix to strengthen its position in biosciences and genetic analysis as well as extend geographic reach of Affymetrix’s products by leveraging Thermo Fisher’s market presence and infrastructure in Asia Pacific, particularly China.

Various new biomarker identification systems and emerging new uses for protein assays provided opportunities to the players in the global protein assay market. For instance, in June 2017, Gyros Protein Technologies AB launched a new version of its anti-drug antibody (ADA) solution for the immunogenicity segment. Gyrolab ADA solution enables to automatically run drug-tolerant ADA assays in a time efficient way reducing hands-on time, using small volumes of patient samples and reagents, and reducing run-times.

Manufacturers are likely to focus on launching systems, which are expected to help understand protein structures and functions, with tools to characterize post-translational modifications, localization, and expression control including epigenetic mechanisms. In June 2015, Thermo Fisher Scientific Inc. introduced Orbitrap Fusion Lumos Tribrid mass spectrometer and in 2017, it launched Integrated Ultraviolet Photo separation (UVPD) that enables specialists to perform substantial and little atom structure assurance on a Lorentz focus (LC) time scale; and new advanced peak determination (APD) calculation that is intended to enhance execution of most proteomic work processes with high peptide and protein ID rates.

To know the latest trends and insights related to protein assays market, click the link below:
https://www.coherentmarketinsights.com/market-insight/protein-assays-market-1087

Key Takeaways of the Protein Assays Market:

The global protein assays market is expected to exhibit a CAGR of 11.5% over the forecast period (2017–2025). This is attributed to increasing collaborations among pharmaceutical companies, academic researchers, regulators, and government organizations across various regions.

Among product type, reagents and kits segment is expected to account for the largest share in the global protein assay market over the forecast period. This is attributed to quick and ready-to-use modifications and the requirement of repeat purchase of reagents.

Among technology types, absorbance-based segment is expected to be largest contributor in terms of revenue to the global market over the forecast period, and this is primarily attributed to expanding effectiveness and accuracy of absorbance-based proteins

Some of the major players involved in global protein assays market are Thermo Fisher Scientific Inc., GE Healthcare, Merck KGaA, Bio-Rad Laboratories, Inc., Lonza, Abcam plc, PerkinElmer Inc., Bio-Techne, BioVision Inc., Cell Signaling Technology, Inc., and Geno Technology Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Mr. Shah
Coherent Market Insights
+1-206-701-6702
email us here


Source: EIN Presswire

Lab-On-A-Chip Market to Surpass US$ 10.25 Billion Threshold by 2025

Coherent Market Insights

Coherent Market Insights

Coherent Market Insights is a leading market research Publisher which offers report on “Lab-On-A-Chip Market to Surpass US$ 10.25 Billion Threshold by 2025”

SEATTLE, WASHINGTON, UNITED STATES, December 18, 2017 /EINPresswire.com/ — The global lab-on-a-chip market, by Application (Genomics, Proteomics, Diagnostics, and Drug Discovery), by Product Type (Reagents & Consumables, Software, and Instrument), by Technology (Microarrays and Microfluidics), by End User (Hospital, Diagnostic Labs, Academic and Research Institutes, Biotechnology, and Pharmaceutical Companies), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 4.09 Bn in 2016 and is projected to exhibit a CAGR of 10.8 % over the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights. Increasing demand for diagnostic test and advancement in technology of lab-on-a-chip device, with wide number of applications, in turn is projected to fuel growth of the lab-on-a-chip market over the forecast period.

Request Sample copy of report@ https://www.coherentmarketinsights.com/insight/request-sample/515

Early detection of diseases help with effective treatment measures. However, diseases such as cancer are difficult to detect, as the symptoms are usually more detectable later stages. Scientists are facing challenges in capturing and analyzing the bioparticles of cancers, as they are very small in size, which fuels demand for lab-on-a-chip in cancer diagnosis. Increasing demand for lab-on-a-chip devices is mainly due to advancements in technology, portability, and re-configurability and applications. Some of the application of lab-on-a-chip devices are flow cytometer lab-on-a-chip for (HIV), immunoassay LoC for bacteria detection, real-time PCR detection chips, DNA chip, gene chip, and cellular analysis chip.

Furthermore, manufacturers are focusing on innovation to tap into emerging markets. For instance, in 2017, scientists of IBM Research are developing lab-on-a-chip nanotechnology that can separate and isolate bioparticles, which are around 20 nanometers in diameter. This in turn, gives access to identify DNA viruses and exosomes. This shows potential of lab-on-a-chip to analyze and reveal the presence of the diseases, even before a person shows the symptoms. Furthermore, in August 2017, Utah’s Brigham Young University used 3D printing technology and microfluidics collectively to develop the smallest viable 3D printed microfluidic device, which can be effective below 100 micrometers, indicating a major innovation in the lab-on-a-chip market.

Browse 30 Market Data Tables and 28 Figures spread through 160 Pages and in-depth TOC on Lab-On-A-Chip Market, by Application (Genomics, Proteomics, Diagnostics, and Drug Discovery), by Product Types (Reagents & Consumables, Software, and Instrument), by Technology (Microarrays and Microfluidics), by End User (Hospital, Diagnostic Labs, Academic and Research Institutes, Biotechnology, and Pharmaceutical Companies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2025

To know the latest trends and insights prevalent in the Lab-on-a-chip market, click the link below:
https://www.coherentmarketinsights.com/market-insight/lab-on-a-chip-market-515

Major players in the healthcare sector are adopting novel technologies to deliver better care. In October 2017, Micronit, Axxicon and Helvoet collaborated to offer a leading development and manufacturing package to support the growing demand for high volume polymer microfluidic products. This is majorly due to rapid development of diagnostic systems by the health care industry. For instance, Micronit provides innovative lab-on-a-chip and MEMS solutions using micro and nanotechnologies.

Furthermore, lab-on-a-chip use smartphones to quickly detect multiple pathogens. In October 2017, the University of Illinois at Urbana-Champaign and University of Washington at Tacoma has developed a novel platform to diagnose infectious diseases at the point-of-care, using a smartphone as the detection instrument.

Key takeaways of the market:

The global lab-on-a-chip market is expected to exhibit a CAGR of 8% over the forecast period (2017–2025), owing to rise in chronic diseases.

Asia Pacific is expected to exhibit a highest growth rate, in terms of revenue, in the global lob-on-a-chip market over the forecast period. This is due to increase in prevalence of chronic diseases such as tuberculosis, which in turn fuels growth of the market in the region. The World Health Organization (WHO) estimated that of the 9 million people who developed TB in 2013, 56% were in the South-East Asia and Western Pacific Regions.

Among product types, instrument segment accounted for 50.42% share of the lab-on-a-chip market in 2016
Some major players operating in the global lab-on-chip market are Takara Bio Inc., Nobel Biocare Services AG, Bio-Rad Laboratories Inc., PerkinElmer Inc., and Cepheid Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Mr. Shah
Coherent Market Insights
+1-206-701-6702
email us here


Source: EIN Presswire

Global Enteral Nutrition Market to Surpass US$ 19.31 Billion by 2025

Coherent Market Insights

Coherent Market Insights

Coherent Market Insights is a leading market research Publisher which offers report on “Global Enteral Nutrition Market to Surpass US$ 19.31 Billion by 2025”.

SEATTLE, WASHINGTON, UNITED STATES, December 18, 2017 /EINPresswire.com/ — Global enteral nutrition market was valued at US$ 13.11 billion in 2016, according to Global Enteral Nutrition Market, by Disease Type (Standard and Chronic), by Age Group (Below 15, 15 to 30, 30 to 45, 45 to 60, and Above 60), by End-use Industry (Hospitals, Clinics, and Long Term Care Facilities), published by Coherent Market Insights. The enteral nutrition market is expected to register a CAGR of 4.47% over the forecast period (2017–2025), to reach US$ 19.31 billion by 2025.

Some of the major factors propelling growth of this market are growing global geriatric population and rising prevalence of chronic diseases including diabetes, cardiovascular diseases, cancer, and others. According to the Centers for Disease Control and Prevention (CDC), in 2016, chronic diseases accounted for most of the deaths in U.S. and are responsible for 7 out of 10 deaths among Americans each year. In addition to this, increasing cases of premature births and malnutrition is expected to support growth of the enteral nutrition market. According to the World Health Organization (WHO), globally, preterm birth is the leading cause of death in children under the age of 5 years and the countries including India, China, U.S., Nigeria, Pakistan, Indonesia, Brazil, Bangladesh and Philippines recorded the highest number of preterm births as of November 2017. Furthermore, increasing advancements in technology such as tubes manufactured from polyurethane or silicone coupled with the development of percutaneous endoscopic gastrostomy techniques and surge in demand for home care services are some of the other factors supporting growth of the market. According to the Agency for Clinical Innovation (ACI), approximately 9000 people received home enteral nutrition (HEN) therapy in New South Wales (NSW), in 2012.

Request Sample copy of report@ https://www.coherentmarketinsights.com/insight/request-sample/1115

Key Trends and Analysis of Enteral Nutrition Market:

Among disease type, chronic was the dominant segment in 2016, and is anticipated to record the fastest growing segment over the forecast period. The segment is further segment into renal, hepatic, diabetic, and others and involves the usage of these disease specific enteral nutrition formula.

Among age group, the market is segmented into below 15, 15 to 30, 30 to 45, 45 to 60, and above 60. Above 60 segment accounted for the largest share in the global enteral nutrition market in 2016, as chronic diseases are more prevalent in geriatric population. According to the data provided by National Council on Aging, in 2016, approximately 90% of the geriatric population suffered from least one chronic disease and nearly 75% suffer from least two. The most common chronic diseases include cancer, diabetes, heart disease, and stroke.

Key Takeaways of the Market:

North America held the dominant position in the global enteral nutrition market in 2016, and was valued at US$ 4.24 Bn, and is projected to register a CAGR of 3.70% in terms of revenue over the forecast period. This is majorly due to the high number of premature births in the region, which is one of the key factors fuelling growth of the enteral nutrition market. Children, born before the 32nd and 34th week of gestation are required to receive a nasogastric tube for feeding right after birth. According to the data provided by the National Center for Biotechnology Information (NCBI), North America witnessed a significant rise in preterm births in 2016. Further, this incidence has recorded a significant growth in the past 25 years. In addition, according to the Centers for Disease Control and Prevention (CDC), in 2016, 1 out of every 10 infants were preterm born in the U.S. This factor is one of the key factors responsible for high growth of the enteral nutrition market in North America.

Europe is expected to record a substantial growth in demand for enteral nutrition over the forecast period. The market is primarily driven by rising incidences of cancer and diabetes in the region. According to Coherent Market Insights, in 2016, over 2.4 million people in the U.K. were affected by cancer, which is anticipated to cross 3.7 million by the end of 2035. Further, according to International Diabetes Federation, in 2015, over 6.5 million in Germany were suffering from diabetes, which is anticipated to grow at a steady rate over the forecast period. These factors are expected to aid in growth of the market.

Major players operating in the global enteral nutrition market include Nestle S.A., Baxter International Inc., B. Braun Holding GmbH & Co. KG, Abbott Laboratories, Groupe Danone, Reckitt Benckiser Group Plc , Perrigo Company Plc., Meiji Seika Pharma Co. Ltd., and Fresenius Kabi AG.

Browse 180 market data tables* and 100 figures* on "Enteral Nutrition Market” – Global forecast to 2025.

To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/enteral-nutrition-market-1115

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Mr. Shah
Coherent Market Insights
+1-206-701-6702
email us here


Source: EIN Presswire

SeamlessMD Qualified to OTN’s Vendor of Record for Surgical Virtual Patient Engagement Solutions

Ontario hospitals can now procure, implement and scale SeamlessMD’s patient engagement technology more quickly

TORONTO, ON, CANADA, December 18, 2017 /EINPresswire.com/ — After a competitive evaluation process, the Ontario Telemedicine Network (OTN) has qualified SeamlessMD as one of three vendors on a new Ontario Vendor of Record (VOR) for mature and market-tested patient engagement technologies that standardize surgical pathways and improve health outcomes. This allows OTN to accelerate the spread of proven, robust patient engagement technology for patients and providers across Ontario.

A rigorous process was applied to qualify SeamlessMD, with a specific focus on selecting virtual care solutions proven to improve the patient experience, decrease length of stay, reduce readmissions and decrease surgical cancellations. An innovation procurement approach was used to establish a VOR arrangement, accessible by all 14 of Ontario’s Local Health Integration Networks (LHINs) and the health and community care providers within these LHINs.

This VOR – which can be accessed through OTN’s Innovation Centre at https://otn.ca/innovationcentre/surgical/ — will enable these organizations to acquire and deploy these virtual care solutions more efficiently because the requirement for an open competitive procurement has been satisfied and therefore the length of the procurement process is significantly reduced.

SeamlessMD’s patient engagement and quality improvement platform is already used at Ontario hospitals including the University Health Network, Sunnybrook Health Sciences Centre, the Ottawa Hospital, and Sinai Health System.

“By leveraging this Vendor of Record, Ontario healthcare organizations will be able to more quickly access validated solutions like SeamlessMD, which contribute to improved patient experience, decreased length of stay, reduced readmissions, and decreased surgical cancellations,” says Dr. Ed Brown, CEO, OTN. “Qualifying SeamlessMD as one of three vendors on the VOR reflects OTN's drive to help healthcare organizations deliver the highest quality patient care."

“With SeamlessMD on the Vendor of Record, Ontario hospitals will be able to leverage technology to elevate the patient experience and drive better health outcomes more quickly. This is an incredible milestone for the Ontario healthcare system, and it is an honour to be the only Canadian company selected by OTN as part of this initiative to advance patient care forward,” says Dr. Joshua Liu, CEO, SeamlessMD and Chair, Joule Innovation Council for the Canadian Medical Association.

ABOUT SEAMLESSMD

SeamlessMD provides the leading Patient Engagement and Quality Improvement platform for health systems to deliver value-based models of care, including Enhanced Recovery After Surgery (ERAS), Perioperative Surgical Home (PSH), prehabilitation, readmissions prevention, bundled payments and Patient Reported Outcome (PRO) data collection. Research completed by academic medical centers has shown SeamlessMD to reduce hospital length of stay, readmissions, ER visits and costs. Accessible via smartphone, tablet or computer, the SeamlessMD platform keeps patients on track from preparation through recovery with reminders, video-based education, progress tracking and PRO data collection. Providers can access real-time dashboards to measure compliance and outcomes, intervene sooner for patients at-risk and drive quality improvement across the organization. For more information, please visit: www.seamless.md.

Alan Sardana
SeamlessMD
1-800-484-0378
email us here


Source: EIN Presswire

Global Health Drink Market 2017 Share, Trend, Segmentation And Forecast To 2022

Health Drink -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2022

PUNE, MAHARASHTRA, INDIA, December 18, 2017 /EINPresswire.com/ — Health Drink Industry

Description

Wiseguyreports.Com Adds “Health Drink -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2022” To Its Research Database

This report studies Health Drink in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering

Coca-Cola
Archer Daniels Midland (ADM)
Campbell Soup
Danone
Del Monte Pacific
Dr. Pepper Snapple Group
Fonterra
GlaxoSmithKline
Kraft Heinz
Monster Beverage
Nestlé
PepsiCo
Yakult
Red Bull
Unilever

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/2404094-global-health-drink-market-professional-survey-report-2017

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Hydration Drinks
Rejuvenation Drinks
Health & Wellness Drinks
Weight Management Drinks

By Application, the market can be split into
Commercial Consumption
Household Consumption
Other

By Regions, this report covers (we can add the regions/countries as you want)
North America
China
Europe
Southeast Asia
Japan
India

Leave a Query @ https://www.wiseguyreports.com/enquiry/2404094-global-health-drink-market-professional-survey-report-2017

Table of Contents

Global Health Drink Market Professional Survey Report 2017
1 Industry Overview of Health Drink
1.1 Definition and Specifications of Health Drink
1.1.1 Definition of Health Drink
1.1.2 Specifications of Health Drink
1.2 Classification of Health Drink
1.2.1 Hydration Drinks
1.2.2 Rejuvenation Drinks
1.2.3 Health & Wellness Drinks
1.2.4 Weight Management Drinks
1.3 Applications of Health Drink
1.3.1 Commercial Consumption
1.3.2 Household Consumption
1.3.3 Other
1.4 Market Segment by Regions
1.4.1 North America
1.4.2 China
1.4.3 Europe
1.4.4 Southeast Asia
1.4.5 Japan
1.4.6 India

….

8 Major Manufacturers Analysis of Health Drink
8.1 Coca-Cola
8.1.1 Company Profile
8.1.2 Product Picture and Specifications
8.1.2.1 Product A
8.1.2.2 Product B
8.1.3 Coca-Cola 2016 Health Drink Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.1.4 Coca-Cola 2016 Health Drink Business Region Distribution Analysis
8.2 Archer Daniels Midland (ADM)
8.2.1 Company Profile
8.2.2 Product Picture and Specifications
8.2.2.1 Product A
8.2.2.2 Product B
8.2.3 Archer Daniels Midland (ADM) 2016 Health Drink Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.2.4 Archer Daniels Midland (ADM) 2016 Health Drink Business Region Distribution Analysis
8.3 Campbell Soup
8.3.1 Company Profile
8.3.2 Product Picture and Specifications
8.3.2.1 Product A
8.3.2.2 Product B
8.3.3 Campbell Soup 2016 Health Drink Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.3.4 Campbell Soup 2016 Health Drink Business Region Distribution Analysis
8.4 Danone
8.4.1 Company Profile
8.4.2 Product Picture and Specifications
8.4.2.1 Product A
8.4.2.2 Product B
8.4.3 Danone 2016 Health Drink Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.4.4 Danone 2016 Health Drink Business Region Distribution Analysis
8.5 Del Monte Pacific
8.5.1 Company Profile
8.5.2 Product Picture and Specifications
8.5.2.1 Product A
8.5.2.2 Product B
8.5.3 Del Monte Pacific 2016 Health Drink Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.5.4 Del Monte Pacific 2016 Health Drink Business Region Distribution Analysis
8.6 Dr. Pepper Snapple Group
8.6.1 Company Profile
8.6.2 Product Picture and Specifications
8.6.2.1 Product A
8.6.2.2 Product B
8.6.3 Dr. Pepper Snapple Group 2016 Health Drink Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.6.4 Dr. Pepper Snapple Group 2016 Health Drink Business Region Distribution Analysis
8.7 Fonterra
8.7.1 Company Profile
8.7.2 Product Picture and Specifications
8.7.2.1 Product A
8.7.2.2 Product B
8.7.3 Fonterra 2016 Health Drink Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.7.4 Fonterra 2016 Health Drink Business Region Distribution Analysis
8.8 GlaxoSmithKline
8.8.1 Company Profile
8.8.2 Product Picture and Specifications
8.8.2.1 Product A
8.8.2.2 Product B
8.8.3 GlaxoSmithKline 2016 Health Drink Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.8.4 GlaxoSmithKline 2016 Health Drink Business Region Distribution Analysis
8.9 Kraft Heinz
8.9.1 Company Profile
8.9.2 Product Picture and Specifications
8.9.2.1 Product A
8.9.2.2 Product B
8.9.3 Kraft Heinz 2016 Health Drink Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.9.4 Kraft Heinz 2016 Health Drink Business Region Distribution Analysis
8.10 Monster Beverage
8.10.1 Company Profile
8.10.2 Product Picture and Specifications
8.10.2.1 Product A
8.10.2.2 Product B
8.10.3 Monster Beverage 2016 Health Drink Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.10.4 Monster Beverage 2016 Health Drink Business Region Distribution Analysis
8.11 Nestlé
8.12 PepsiCo
8.13 Yakult
8.14 Red Bull
8.15 Unilever

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=2404094

Continued…

Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us) Ph: +44 208 133 9349 (Uk)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Amarillo, Texas Doctor Selected to the "America's Best Physicians" 2017 Directory

Dr. Neel Kanase

Dr. Neel Kanase, MD listed as Top Doctor in Medical Spa & Cosmetic Procedures

Dr. Neel Kanase, MD Selected as Best for Medical Spa & Cosmetic Techniques”

— TodaysBestPhysicians.com

AMARILLO , TEXAS , UNITED STATES, December 18, 2017 /EINPresswire.com/ — Amarillo, Texas doctor, Dr. Neel Kanase has been selected to the "America's Best Physicians" registry for 2017. Selections were made by the National Consumer Advisory Board, an organization that identifies top professionals in their fields. Dr. Kanase practices at the American Laser Med Spa at 1200 Wallace Blvd. in Amarillo, serving patients in the Texas Panhandle, as well as, the Lubbock, Midland, El Paso and Corpus Christi areas.

Services include: Laser Hair Removal, CoolSculpting® Fat Reduction, Juvederm, Botox, Microneedling and UltraSonic Facials.

Dr. Kanase received his Medical degree (MD) from Grant Medical College and completed his Masters in Food and Nutrition at Texas Tech University in Lubbock. He received his residency training in Family Medicine at Texas Tech Health Sciences Center in Amarillo, where he was named chief resident. Dr. Kanase has won numerous awards, including “Outstanding Graduating Resident of the Year” and selection as “Outstanding Resident Teacher”.

Dr. Kanase is a fellow of the American Society for Laser Medicine and Surgery. He is a recipient of the American Medical Association’s Physician Recognition Award. He is a former Chief of Medical Staff at Dallam Hartley County Hospital and has been selected for “America’s Top Family Doctors”.

Dr. Kanase co-authored the top-selling book “Soul Of Success” with Jack Canfield, the well-known author of “Chicken Soup for the Soul”.

For more information, please go to www.TodaysBestPhysicians.com or contact Dr. Neel Kanase, MD directly at 806-356-7729 or americanlasermedspa.com.

The "National Consumer Advisory Board" accepts no fees, sponsorships, donations or advertising in their selection process. Doctors were chosen following an application based on training, experience, continuing education, and dedication to excellence. Only Doctors that satisfy all of the board's criteria can qualify for inclusion in the "Americas Best Physicians" directory.

TodaysBestPhysicians.com
Americas Best Physicians
5555555555
email us here


Source: EIN Presswire

Augmented and Virtual Reality Healthcare Market 2017 Global Key Players, Trend, Share and Opportunities Forecast 2022

Augmented and Virtual Reality Healthcare Global Market 2017: Key Players Google, Microsoft, DAQRI, Psious, Mindmaze

PUNE, INDIA, December 18, 2017 /EINPresswire.com/ — In this report, the global Augmented and Virtual Reality in Healthcare market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Augmented and Virtual Reality in Healthcare for these regions, from 2012 to 2022 (forecast), covering
United States
China
Europe
Japan
Southeast Asia
India

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2579762-global-augmented-and-virtual-reality-in-healthcare-sales-market-report-2017

Global Augmented and Virtual Reality in Healthcare market competition by top manufacturers/players, with Augmented and Virtual Reality in Healthcare sales volume, Price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including
Google (US)
Microsoft (US)
DAQRI (US)
Psious (Spain)
Mindmaze (Switzerland)
Firsthand Technology (US)
Medical Realities (UK)
Atheer (US)
Augmedix (US)
Oculus VR (US)
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Hardware
Software
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Augmented and Virtual Reality in Healthcare for each application, including
Patient Care Management
Medical Training & Education
Pharmacy Management
Surgery

Table of Content: Key Points

Global Augmented and Virtual Reality in Healthcare Sales Market Report 2017
1 Augmented and Virtual Reality in Healthcare Market Overview
1.1 Product Overview and Scope of Augmented and Virtual Reality in Healthcare
1.2 Classification of Augmented and Virtual Reality in Healthcare by Product Category
1.2.1 Global Augmented and Virtual Reality in Healthcare Market Size (Sales) Comparison by Type (2012-2022)
1.2.2 Global Augmented and Virtual Reality in Healthcare Market Size (Sales) Market Share by Type (Product Category) in 2016
1.2.3 Hardware
1.2.4 Software
1.3 Global Augmented and Virtual Reality in Healthcare Market by Application/End Users
1.3.1 Global Augmented and Virtual Reality in Healthcare Sales (Volume) and Market Share Comparison by Application (2012-2022)
1.3.2 Patient Care Management
1.3.3 Medical Training & Education
1.3.4 Pharmacy Management
1.3.5 Surgery
1.4 Global Augmented and Virtual Reality in Healthcare Market by Region
1.4.1 Global Augmented and Virtual Reality in Healthcare Market Size (Value) Comparison by Region (2012-2022)
1.4.2 United States Augmented and Virtual Reality in Healthcare Status and Prospect (2012-2022)
1.4.3 China Augmented and Virtual Reality in Healthcare Status and Prospect (2012-2022)
1.4.4 Europe Augmented and Virtual Reality in Healthcare Status and Prospect (2012-2022)
1.4.5 Japan Augmented and Virtual Reality in Healthcare Status and Prospect (2012-2022)
1.4.6 Southeast Asia Augmented and Virtual Reality in Healthcare Status and Prospect (2012-2022)
1.4.7 India Augmented and Virtual Reality in Healthcare Status and Prospect (2012-2022)
1.5 Global Market Size (Value and Volume) of Augmented and Virtual Reality in Healthcare (2012-2022)
1.5.1 Global Augmented and Virtual Reality in Healthcare Sales and Growth Rate (2012-2022)
1.5.2 Global Augmented and Virtual Reality in Healthcare Revenue and Growth Rate (2012-2022)

2 Global Augmented and Virtual Reality in Healthcare Competition by Players/Suppliers, Type and Application
2.1 Global Augmented and Virtual Reality in Healthcare Market Competition by Players/Suppliers
2.1.1 Global Augmented and Virtual Reality in Healthcare Sales and Market Share of Key Players/Suppliers (2012-2017)
2.1.2 Global Augmented and Virtual Reality in Healthcare Revenue and Share by Players/Suppliers (2012-2017)
2.2 Global Augmented and Virtual Reality in Healthcare (Volume and Value) by Type
2.2.1 Global Augmented and Virtual Reality in Healthcare Sales and Market Share by Type (2012-2017)
2.2.2 Global Augmented and Virtual Reality in Healthcare Revenue and Market Share by Type (2012-2017)
2.3 Global Augmented and Virtual Reality in Healthcare (Volume and Value) by Region
2.3.1 Global Augmented and Virtual Reality in Healthcare Sales and Market Share by Region (2012-2017)
2.3.2 Global Augmented and Virtual Reality in Healthcare Revenue and Market Share by Region (2012-2017)
2.4 Global Augmented and Virtual Reality in Healthcare (Volume) by Application

9 Global Augmented and Virtual Reality in Healthcare Players/Suppliers Profiles and Sales Data
9.1 Google (US)
9.1.1 Company Basic Information, Manufacturing Base and Competitors
9.1.2 Augmented and Virtual Reality in Healthcare Product Category, Application and Specification
9.1.2.1 Product A
9.1.2.2 Product B
9.1.3 Google (US) Augmented and Virtual Reality in Healthcare Sales, Revenue, Price and Gross Margin (2012-2017)
9.1.4 Main Business/Business Overview
9.2 Microsoft (US)
9.2.1 Company Basic Information, Manufacturing Base and Competitors
9.2.2 Augmented and Virtual Reality in Healthcare Product Category, Application and Specification
9.2.2.1 Product A
9.2.2.2 Product B
9.2.3 Microsoft (US) Augmented and Virtual Reality in Healthcare Sales, Revenue, Price and Gross Margin (2012-2017)
9.2.4 Main Business/Business Overview
9.3 DAQRI (US)
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2579762-global-augmented-and-virtual-reality-in-healthcare-sales-market-report-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global Cholesterol Screening/ Cholesterol Lab Testing Market 2017 Share, Trend, Segmentation and Forecast to 2022

Cholesterol Screening/ Cholesterol Lab Testing Market 2017 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2022

PUNE, MAHARASHTRA, INDIA, December 18, 2017 /EINPresswire.com/ — Summary

WiseGuyReports.com adds “Cholesterol Screening/ Cholesterol Lab Testing Market 2017 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2022” reports to its database.

This report provides in depth study of “Cholesterol Screening/ Cholesterol Lab Testing market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Cholesterol Screening/ Cholesterol Lab Testing Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization.

This report studies the global Cholesterol Screening/ Cholesterol Lab Testing market, analyzes and researches the Cholesterol Screening/ Cholesterol Lab Testing development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like
Laboratory Corporation of America Holdings
Quest Diagnostics
Eurofins Scientific
Spectra Laboratories
Unilabs
Synlab International
Bio-Reference Laboratories
Clinical Reference Laboratory
ACM Medical Laboratory
Adicon Clinical Laboratory

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/2576662-global-cholesterol-screening-cholesterol-lab-testing-market-size-status-and-forecast

Market segment by Regions/Countries, this report covers
United States
EU
Japan
China
India
Southeast Asia

Market segment by Type, the product can be split into
Hospital
Clinical Laboratories
Other

Market segment by Application, Cholesterol Screening/ Cholesterol Lab Testing can be split into
Physicians/Providers and Hospitals
Managed Care Organizations (MCOs)
Government Agencies
Patients

At any Query @ https://www.wiseguyreports.com/enquiry/2576662-global-cholesterol-screening-cholesterol-lab-testing-market-size-status-and-forecast

Table of Contents

Global Cholesterol Screening/ Cholesterol Lab Testing Market Size, Status and Forecast 2022
1 Industry Overview of Cholesterol Screening/ Cholesterol Lab Testing
1.1 Cholesterol Screening/ Cholesterol Lab Testing Market Overview
1.1.1 Cholesterol Screening/ Cholesterol Lab Testing Product Scope
1.1.2 Market Status and Outlook
1.2 Global Cholesterol Screening/ Cholesterol Lab Testing Market Size and Analysis by Regions
1.2.1 United States
1.2.2 EU
1.2.3 Japan
1.2.4 China
1.2.5 India
1.2.6 Southeast Asia
1.3 Cholesterol Screening/ Cholesterol Lab Testing Market by Type
1.3.1 Hospital
1.3.2 Clinical Laboratories
1.3.3 Other
1.4 Cholesterol Screening/ Cholesterol Lab Testing Market by End Users/Application
1.4.1 Physicians/Providers and Hospitals
1.4.2 Managed Care Organizations (MCOs)
1.4.3 Government Agencies
1.4.4 Patients

2 Global Cholesterol Screening/ Cholesterol Lab Testing Competition Analysis by Players
2.1 Cholesterol Screening/ Cholesterol Lab Testing Market Size (Value) by Players (2016 and 2017)
2.2 Competitive Status and Trend
2.2.1 Market Concentration Rate
2.2.2 Product/Service Differences
2.2.3 New Entrants
2.2.4 The Technology Trends in Future

3 Company (Top Players) Profiles
3.1 Laboratory Corporation of America Holdings
3.1.1 Company Profile
3.1.2 Main Business/Business Overview
3.1.3 Products, Services and Solutions
3.1.4 Cholesterol Screening/ Cholesterol Lab Testing Revenue (Value) (2012-2017)
3.1.5 Recent Developments
3.2 Quest Diagnostics
3.2.1 Company Profile
3.2.2 Main Business/Business Overview
3.2.3 Products, Services and Solutions
3.2.4 Cholesterol Screening/ Cholesterol Lab Testing Revenue (Value) (2012-2017)
3.2.5 Recent Developments
3.3 Eurofins Scientific
3.3.1 Company Profile
3.3.2 Main Business/Business Overview
3.3.3 Products, Services and Solutions
3.3.4 Cholesterol Screening/ Cholesterol Lab Testing Revenue (Value) (2012-2017)
3.3.5 Recent Developments
3.4 Spectra Laboratories
3.4.1 Company Profile
3.4.2 Main Business/Business Overview
3.4.3 Products, Services and Solutions
3.4.4 Cholesterol Screening/ Cholesterol Lab Testing Revenue (Value) (2012-2017)
3.4.5 Recent Developments
3.5 Unilabs
3.5.1 Company Profile
3.5.2 Main Business/Business Overview
3.5.3 Products, Services and Solutions
3.5.4 Cholesterol Screening/ Cholesterol Lab Testing Revenue (Value) (2012-2017)
3.5.5 Recent Developments
3.6 Synlab International
3.6.1 Company Profile
3.6.2 Main Business/Business Overview
3.6.3 Products, Services and Solutions
3.6.4 Cholesterol Screening/ Cholesterol Lab Testing Revenue (Value) (2012-2017)
3.6.5 Recent Developments
3.7 Bio-Reference Laboratories
3.7.1 Company Profile
3.7.2 Main Business/Business Overview
3.7.3 Products, Services and Solutions
3.7.4 Cholesterol Screening/ Cholesterol Lab Testing Revenue (Value) (2012-2017)
3.7.5 Recent Developments
3.8 Clinical Reference Laboratory
3.8.1 Company Profile
3.8.2 Main Business/Business Overview
3.8.3 Products, Services and Solutions
3.8.4 Cholesterol Screening/ Cholesterol Lab Testing Revenue (Value) (2012-2017)
3.8.5 Recent Developments
3.9 ACM Medical Laboratory
3.9.1 Company Profile
3.9.2 Main Business/Business Overview
3.9.3 Products, Services and Solutions
3.9.4 Cholesterol Screening/ Cholesterol Lab Testing Revenue (Value) (2012-2017)
3.9.5 Recent Developments
3.10 Adicon Clinical Laboratory
3.10.1 Company Profile
3.10.2 Main Business/Business Overview
3.10.3 Products, Services and Solutions
3.10.4 Cholesterol Screening/ Cholesterol Lab Testing Revenue (Value) (2012-2017)
3.10.5 Recent Developments

4 Global Cholesterol Screening/ Cholesterol Lab Testing Market Size by Type and Application (2012-2017)
4.1 Global Cholesterol Screening/ Cholesterol Lab Testing Market Size by Type (2012-2017)
4.2 Global Cholesterol Screening/ Cholesterol Lab Testing Market Size by Application (2012-2017)
4.3 Potential Application of Cholesterol Screening/ Cholesterol Lab Testing in Future
4.4 Top Consumer/End Users of Cholesterol Screening/ Cholesterol Lab Testing

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=2576662

Continued….

Contact Us: sales@wiseguyreports.com

Ph: +1-646-845-9349 (US) ; Ph: +44 208 133 9349 (UK)

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire